| Identification | Back Directory | [Name]
2-(2-Methylphenoxy)-4H-1,3,2-benzodioxaphosphorin 2-oxide | [CAS]
1222-87-3 | [Synonyms]
cbdp
o-Tolyl saligenin phosphate
2-(o-cresyl)-4h-1,3,2-benzodioxaphoran-2-one
2-(2-cresyl)-4h-1-3-2-benzodioxaphosphorin-2-oxide
3,2-benzodioxaphosphorin,2-(o-tolyloxy)-4h-2-oxide
phosphoricacid,cyclicmethylene-o-phenyleneo-tolylester
3,2-benzodioxaphosphorin,2-(2-methylphenoxy)-4h-2-oxide
2-(2-METHYLPHENOXY)-4H-1,3,2-BENZODIOXAPHOSPHORIN 2-OXIDE
2-(o-Tolyloxy)-4H-benzo[d][1,3,2]dioxaphosphinine 2-Oxide
4H-1,3,2-Benzodioxaphosphorin, 2-(2-methylphenoxy)-, 2-oxide | [Molecular Formula]
C14H13O4P | [MDL Number]
MFCD00798815 | [MOL File]
1222-87-3.mol | [Molecular Weight]
276.22 |
| Hazard Information | Back Directory | [Uses]
Plasma carboxylic-ester hydrolase (EC3.1.1.1) is a very important detoxification route for the toxic stereoisomers of soman. Detoxification is meant in the sense that if soman was bound to carbox-ylic-ester hydrolase, it was not free to inhibit acetylcholinesterase. CBDP (2-(2-Methylphenoxy)-4H-1,3,2-benzodioxaphosphorin 2-oxide) pretreatment, which inhibited irreversibly carboxylic-ester hydrolase activity without inhibiting phosphoryl phosphatase activity, potentiated the toxicity of soman in mice. In toxicity experiments, CBDP (0.5 mg/kg; iv 1 hr prior to soman) pretreatment potentiated the toxicity of C(±)P(±)-, C(+)P(?)-, and C(?)P(?)-soman to a similar degree[1].
| [References]
[1] John G. Clement. “Stereoisomers of soman (pinacolyl methylphosphonofluoridate): Inhibition of serum carboxylic ester hydrolase and potentiation of their toxicity by CBDP (2-(2-methylphenoxy)-4H-1,3,2-benzodioxaphosphorin-2-oxide) in mice.” Toxicology and applied pharmacology 89 1 (1987): Pages 141-143. |
|
|